These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 31021904)

  • 1. Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China).
    Tan X; Wen F; Yang W; Xie JY; Ding LL; Mo YX
    Menopause; 2019 Aug; 26(8):929-939. PubMed ID: 31021904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.
    Barrionuevo P; Kapoor E; Asi N; Alahdab F; Mohammed K; Benkhadra K; Almasri J; Farah W; Sarigianni M; Muthusamy K; Al Nofal A; Haydour Q; Wang Z; Murad MH
    J Clin Endocrinol Metab; 2019 May; 104(5):1623-1630. PubMed ID: 30907957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.
    Händel MN; Cardoso I; von Bülow C; Rohde JF; Ussing A; Nielsen SM; Christensen R; Body JJ; Brandi ML; Diez-Perez A; Hadji P; Javaid MK; Lems WF; Nogues X; Roux C; Minisola S; Kurth A; Thomas T; Prieto-Alhambra D; Ferrari SL; Langdahl B; Abrahamsen B
    BMJ; 2023 May; 381():e068033. PubMed ID: 37130601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy and safety of drug interventions for primary and secondary prevention of osteoporotic fractures in postmenopausal women: Network meta-analysis followed by factor and cluster analysis.
    Wen F; Du H; Ding L; Hu J; Huang Z; Huang H; Li K; Mo Y; Kuang A
    PLoS One; 2020; 15(6):e0234123. PubMed ID: 32492050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
    Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
    Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
    Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
    Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses.
    Zhou J; Ma X; Wang T; Zhai S
    Osteoporos Int; 2016 Nov; 27(11):3289-3300. PubMed ID: 27273112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis.
    Reginster J-; Bianic F; Campbell R; Martin M; Williams SA; Fitzpatrick LA
    Osteoporos Int; 2019 Jul; 30(7):1465-1473. PubMed ID: 30953114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis.
    Yang L; Kang N; Yang JC; Su QJ; Liu YZ; Guan L; Liu T; Meng XL; Wang Y; Hai Y
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2640-2668. PubMed ID: 30964193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
    Zhang L; Pang Y; Shi Y; Xu M; Xu X; Zhang J; Ji L; Zhao D
    Menopause; 2015 Sep; 22(9):1021-5. PubMed ID: 25944523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis.
    Freemantle N; Cooper C; Diez-Perez A; Gitlin M; Radcliffe H; Shepherd S; Roux C
    Osteoporos Int; 2013 Jan; 24(1):209-17. PubMed ID: 22832638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis.
    Adams A; Jakob T; Huth A; Monsef I; Ernst M; Kopp M; Caro-Valenzuela J; Wöckel A; Skoetz N
    Cochrane Database Syst Rev; 2024 Jul; 7(7):CD013451. PubMed ID: 38979716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
    Ayers C; Kansagara D; Lazur B; Fu R; Kwon A; Harrod C
    Ann Intern Med; 2023 Feb; 176(2):182-195. PubMed ID: 36592455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
    Moshi MR; Nicolopoulos K; Stringer D; Ma N; Jenal M; Vreugdenburg T
    Calcif Tissue Int; 2023 Jun; 112(6):631-646. PubMed ID: 37016189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials.
    Wang WY; Chen LH; Ma WJ; You RX
    Eur Rev Med Pharmacol Sci; 2023 Sep; 27(17):8253-8268. PubMed ID: 37750653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
    Albert SG; Reddy S
    Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
    Levis S; Theodore G
    J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoporosis drugs for prevention of clinical fracture in white postmenopausal women: a network meta-analysis of survival data.
    Ding LL; Wen F; Wang H; Wang DH; Liu Q; Mo YX; Tan X; Qiu M; Hu JX
    Osteoporos Int; 2020 May; 31(5):961-971. PubMed ID: 32002571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
    Cosman F; Crittenden DB; Adachi JD; Binkley N; Czerwinski E; Ferrari S; Hofbauer LC; Lau E; Lewiecki EM; Miyauchi A; Zerbini CA; Milmont CE; Chen L; Maddox J; Meisner PD; Libanati C; Grauer A
    N Engl J Med; 2016 Oct; 375(16):1532-1543. PubMed ID: 27641143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.